Deal adds a marketed small molecule and three pipeline agents, although Lilly will share revenue from Vitrakvi and LOXO-195 with Bayer.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Two oncology specialists, Epizyme and Clovis, have been punished for ongoing problems.
Glaxosmithkline is trying to reinvent itself as an oncology company – but it will need to make bolder deals if it wants to succeed.
Epigenetics has so far failed to live up to the hype. But one UK player, Storm Therapeutics, still hopes to make a mark in a new field, RNA therapeutics.
2018 shaping up to be a bumper approval year, as Juno Therapeutics, Epizyme and Avexis line up to launch potential blockbusters.